Abeona Therapeutics Inc.
ABEO
$4.68
$0.235.17%
| Weiss Ratings | ABEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ABEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ABEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.27 | |||
| Price History | ABEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -8.59% | |||
| 30-Day Total Return | -20.14% | |||
| 60-Day Total Return | -22.26% | |||
| 90-Day Total Return | -20.54% | |||
| Year to Date Total Return | -20.81% | |||
| 1-Year Total Return | -37.43% | |||
| 2-Year Total Return | 65.37% | |||
| 3-Year Total Return | -43.10% | |||
| 5-Year Total Return | -91.13% | |||
| 52-Week High % Change | -47.34% | |||
| 52-Week Low % Change | 45.90% | |||
| Price | ABEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $8.45 | |||
| 52-Week Low Price | $3.05 | |||
| 52-Week Low Price (Date) | Apr 25, 2024 | |||
| 52-Week High Price (Date) | Apr 17, 2024 | |||
| Valuation | ABEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 215.98M | |||
| Enterprise Value | 141.30M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.24 | |||
| Earnings Per Share Growth | -13.42% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 4.61 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $4.68 | |||
| Enterprise Value/EBITDA (TTM) | -2.27 | |||
| Enterprise Value/EBIT | -2.20 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | ABEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 48.68M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ABEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 646 813 4701 | |||
| Address | 6555 Carnegie Avenue Cleveland, OH 44103 | |||
| Website | www.abeonatherapeutics.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | ABEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | ABEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -46.41% | |||
| Return on Equity | -- | |||
| Income Statement | ABEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -41.22M | |||
| EBITDA (TTM) | -62.21M | |||
| EBIT (TTM) | -64.21M | |||
| Net Income (TTM) | -63.73M | |||
| Net Income Avl. to Common (TTM) | -63.73M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 43.99% | |||
| EPS Diluted (TTM) | -2.24 | |||
| EPS Diluted Growth (Q YOY) | 70.44% | |||
| Balance Sheet | ABEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 97.72M | |||
| Cash Per Share (Q) | $2.01 | |||
| Total Current Assets (Q) | 100.85M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 44.03M | |||
| Current Ratio (Q) | 6.080 | |||
| Book Value Per Share (Q) | $0.96 | |||
| Total Assets (Q) | 108.93M | |||
| Total Current Liabilities (Q) | 16.59M | |||
| Total Debt (Q) | 23.05M | |||
| Total Liabilities (Q) | 64.90M | |||
| Total Common Equity (Q) | 44.03M | |||
| Cash Flow | ABEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -39.24M | |||
| Cash from Financing (TTM) | 104.14M | |||
| Net Change in Cash (TTM) | 8.88M | |||
| Levered Free Cash Flow (TTM) | -37.86M | |||
| Cash from Operations (TTM) | -56.02M | |||
